Actuate Therapeutics (NASDAQ:ACTU) Issues Quarterly Earnings Results

Actuate Therapeutics (NASDAQ:ACTU) posted its quarterly earnings data on Friday. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.01, FiscalAI reports.

Actuate Therapeutics Stock Up 3.6%

Shares of NASDAQ:ACTU traded up $0.03 during trading on Friday, reaching $1.01. 109,613 shares of the company traded hands, compared to its average volume of 179,496. The company’s 50 day moving average is $1.49 and its two-hundred day moving average is $2.49. The firm has a market capitalization of $24.17 million, a PE ratio of -1.04 and a beta of 0.78. Actuate Therapeutics has a 52 week low of $0.90 and a 52 week high of $9.22.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Voss Capital LP grew its stake in Actuate Therapeutics by 45.0% during the fourth quarter. Voss Capital LP now owns 1,300,000 shares of the company’s stock worth $7,956,000 after buying an additional 403,722 shares in the last quarter. Bridgeway Capital Management LLC bought a new position in shares of Actuate Therapeutics in the fourth quarter worth about $190,000. Goldman Sachs Group Inc. lifted its holdings in shares of Actuate Therapeutics by 98.7% in the first quarter. Goldman Sachs Group Inc. now owns 22,358 shares of the company’s stock worth $151,000 after acquiring an additional 11,105 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Actuate Therapeutics by 61.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 23,841 shares of the company’s stock valued at $146,000 after purchasing an additional 9,076 shares in the last quarter. Finally, New York State Common Retirement Fund acquired a new stake in shares of Actuate Therapeutics in the 2nd quarter valued at approximately $105,000.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Wall Street Zen downgraded shares of Actuate Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 23rd. HC Wainwright reiterated a “buy” rating on shares of Actuate Therapeutics in a research note on Wednesday, June 10th. Weiss Ratings reissued a “sell (e+)” rating on shares of Actuate Therapeutics in a report on Wednesday, June 24th. Finally, Rodman & Renshaw began coverage on shares of Actuate Therapeutics in a research report on Thursday, July 30th. They set a “buy” rating and a $6.00 target price on the stock. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $13.67.

Actuate Therapeutics Company Profile

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.